Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers
Objective Axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, is metabolized primarily by cytochrome P450 (CYP) 3A with minor contributions from CYP1A2, CYP2C19, and glucuronidation. Co-administration with CYP inhibitors may inc...
Main Authors: | , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Springer US
2010
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256319/ |